ArticleClinical rheumatology2025
Hyperuricemia is a prognostic marker for antiphospholipid syndrome patients: a retrospective cohort study in China.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveHyperuricemia (HUA) is implicated in inflammation and a prothrombotic state, but its prognostic role in antiphospholipid syndrome (APS) remains uncertain. This study aims to evaluate the prognostic value of HUA in APS and identify optimal serum uric acid (SUA) thresholds for predicting adverse outcomes.
methodsAll patients fulfilled the 2006 Sydney criteria for APS were followed up at Peking University People's Hospital (2009-2022). Patients with persistent HUA were included in the HUA group. Comparative analyses were conducted between APS patients with and without HUA. Subgroup and ROC analyses were performed to evaluate prognostic value and identify optimal SUA thresholds.
resultsAmong 240 primary APS patients, 45 (18.8%) had HUA. APS patients with HUA had a significantly higher 10-year cumulative all-cause mortality (60.8% vs. 6.6%, P = 0.002), APS-related mortality (45.2% vs. 2.0%, P = 0.004), and thrombosis recurrence rates (40.3% vs. 17.2%, P = 0.005). Multivariate Cox mortality analysis showed that HUA was significantly associated with 10-year cumulative all-cause mortality (HR = 6.408, P = 0.010), APS-related mortality (HR = 15.409, P = 0.031), and thrombosis recurrence rates (HR = 3.227, P = 0.014). SUA thresholds predicting all-cause mortality (8.7 mg/dL, OR = 44.121, P < 0.001) and thrombosis recurrence (5.6 mg/dL, OR = 4.145, P = 0.004) were identified.
conclusionsHUA is associated with a higher risk of adverse outcomes in APS patients. SUA thresholds of 8.7 mg/dL and 5.6 mg/dL may serve as predictors of mortality and thrombotic recurrence, providing potential insights for risk stratification and management in APS. Key Points • APS patients with HUA have higher 10-year cumulative mortality and thrombotic recurrence rates. • HUA may serve as a prognostic marker for APS patients. • SUA thresholds of 8.7 mg/dL and 5.6 mg/dL may serve as predictors of mortality and thrombotic recurrence. • Our observations remind clinicians to focus on APS patients with HUA, and adopt appropriate strategies to reduce the recurrence of thrombosis and mortality.
Indexed as
Identifiers
40493318What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.